182 related articles for article (PubMed ID: 37382562)
1. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Han X; Zhao L; Xiang W; Miao B; Qin C; Wang M; Xu T; McEachern D; Lu J; Wang Y; Metwally H; Yang CY; Kirchhoff PD; Wang L; Matvekas A; Takyi-Williams J; Wen B; Sun D; Ator M; Mckean R; Wang S
J Med Chem; 2023 Jul; 66(13):8822-8843. PubMed ID: 37382562
[TBL] [Abstract][Full Text] [Related]
2. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
[TBL] [Abstract][Full Text] [Related]
3. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
Xiang W; Zhao L; Han X; Xu T; Kregel S; Wang M; Miao B; Qin C; Wang M; McEachern D; Lu J; Bai L; Yang CY; Kirchhoff PD; Takyi-Williams J; Wang L; Wen B; Sun D; Ator M; Mckean R; Chinnaiyan AM; Wang S
J Med Chem; 2023 Sep; 66(18):13280-13303. PubMed ID: 37683104
[TBL] [Abstract][Full Text] [Related]
4. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Xiang W; Zhao L; Han X; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Kirchhoff PD; Wang L; Matvekas A; He M; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(18):13487-13509. PubMed ID: 34473519
[TBL] [Abstract][Full Text] [Related]
5. Discovery of
Zhang B; Liu C; Yang Z; Zhang S; Hu X; Li B; Mao M; Wang X; Li Z; Ma S; Zhang S; Qin C
J Med Chem; 2023 Aug; 66(16):11158-11186. PubMed ID: 37556600
[TBL] [Abstract][Full Text] [Related]
6. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
Han X; Zhao L; Xiang W; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Wang L; Matvekas A; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(17):12831-12854. PubMed ID: 34431670
[TBL] [Abstract][Full Text] [Related]
7. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
9. A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo.
Zhao L; Han X; Lu J; McEachern D; Wang S
Neoplasia; 2020 Oct; 22(10):522-532. PubMed ID: 32928363
[TBL] [Abstract][Full Text] [Related]
10. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
[TBL] [Abstract][Full Text] [Related]
11. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
Hung CL; Liu HH; Fu CW; Yeh HH; Hu TL; Kuo ZK; Lin YC; Jhang MR; Hwang CS; Hsu HC; Kung HJ; Wang LY
EBioMedicine; 2023 Apr; 90():104500. PubMed ID: 36893587
[TBL] [Abstract][Full Text] [Related]
12. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract][Full Text] [Related]
13. Targeting androgen receptor degradation with PROTACs from bench to bedside.
Jia X; Han X
Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
[TBL] [Abstract][Full Text] [Related]
14. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
Takwale AD; Jo SH; Jeon YU; Kim HS; Shin CH; Lee HK; Ahn S; Lee CO; Du Ha J; Kim JH; Hwang JY
Eur J Med Chem; 2020 Dec; 208():112769. PubMed ID: 32961381
[TBL] [Abstract][Full Text] [Related]
15. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
[TBL] [Abstract][Full Text] [Related]
16. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer.
Wu Y; Xue J; Li J
Arch Biochem Biophys; 2022 May; 721():109194. PubMed ID: 35337811
[TBL] [Abstract][Full Text] [Related]
17. The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.
Li L; Xu J
Clin Transl Oncol; 2023 Feb; 25(2):352-363. PubMed ID: 36203075
[TBL] [Abstract][Full Text] [Related]
18. De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy.
Ma B; Fan Y; Zhang D; Wei Y; Jian Y; Liu D; Wang Z; Gao Y; Ma J; Chen Y; Xu S; Li L
Adv Sci (Weinh); 2022 Oct; 9(28):e2201859. PubMed ID: 35971165
[TBL] [Abstract][Full Text] [Related]
19. PROTAC Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration.
Wang R; Zhong T; Bian Q; Zhang S; Ma X; Li L; Xu Y; Gu Y; Yuan A; Hu W; Qin C; Gao J
Small Methods; 2023 Jan; 7(1):e2201293. PubMed ID: 36538748
[TBL] [Abstract][Full Text] [Related]
20. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
